{"nctId":"NCT02272413","briefTitle":"Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer","startDateStruct":{"date":"2015-07-08","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"count":671,"armGroups":[{"label":"BI 695502","type":"EXPERIMENTAL","interventionNames":["Drug: BI 695502"]},{"label":"Avastin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Avastin"]}],"interventions":[{"name":"BI 695502","otherNames":[]},{"name":"Avastin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nAdult patients aged \\>=18 years with histologically or cytologically confirmed advanced nonsquamous non-small cell lung cancer (nsNSCLC). Mixed tumors should be categorized according to the predominant histology.\n\nNote: NSCLC should be predominantly nonsquamous. Recurrent or metastatic disease (Stage IV) with an indication for therapy with paclitaxel + carboplatin + Avastin®.\n\nPatients harboring tumors with unknown or without activating epidermal growth factor receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe included provided chemotherapy is standard of care. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on independent central review.\n\nEastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.\n\nAdequate hepatic, renal, and bone marrow function:\n\nLife expectancy \\> 6 months based on clinical judgment. Further inclusion criteria apply.\n\nExclusion criteria:\n\nPrior therapy with monoclonal antibodies or small molecule inhibitors against Vascular Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastin®.\n\nPrior systemic therapy for metastatic disease. Prior systemic anticancer therapy or radiotherapy for locally advanced nsNSCLC if completed \\<12 months prior to Screening.\n\nPrevious malignancy other than NSCLC in the last 5 years except for basal cell cancer of the skin or pre-invasive cancer of the cervix.\n\nSymptomatic brain metastasis. Diagnosis of small cell carcinoma of the lung, squamous cell carcinoma of the lung, NSCLC not specified (NS) or NSCLC not otherwise specified(NOS).\n\nAny unresolved toxicity \\> Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy).\n\nHistory or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding. Thrombotic or hemorrhagic event =\\< 6 months prior to Screening. Further exclusion criteria apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Best Overall Response Rate (ORR), Based on Unconfirmed Response Assessment, as Assessed by Central Imaging Review Until 18 Weeks After the Start of Treatment","description":"ORR was defined as the percentage of patients who achieved at least one visit response of complete response (CR) or partial response (PR) after the start of treatment. The response criteria evaluation was carried out according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CR and PR did not need to be confirmed by a subsequent tumor assessment due to blinded central assessment. CR: Disappearance of all target lesions since baseline; PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Tumor assessments were performed prior to trial drug administration, until 18 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null},{"groupId":"OG001","value":"63.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Selected Treatment-Emergent Adverse Events (TEAEs) For Comparability Assessment of BI 695502 and US-licensed Avastin®","description":"The following selected adverse events (AEs) were evaluated for comparability assessment of BI 695502 and US-licensed Avastin®:\n\n* Infusion reactions (anaphylactic/hypersensitivity/infusion-related reactions),\n* Thromboembolic events (arterial or venous),\n* Febrile neutropenia,\n* Gastrointestinal perforations,\n* Hypertension,\n* Proteinuria,\n* Pulmonary hemorrhage,\n* Other hemorrhages (not including pulmonary hemorrhages),\n* Wound-healing complications/abscess/fistulas. The analysis of AEs was based on the concept of TEAEs. For non-switched patients, all AEs that started or worsened in severity on or after the first dose of trial drug and prior to the date of last administration of trial medication + 16 weeks inclusive were defined as TEAEs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.50","spread":null},{"groupId":"OG001","value":"45.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.70","spread":null},{"groupId":"OG001","value":"13.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.60","spread":null},{"groupId":"OG001","value":"5.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.90","spread":null},{"groupId":"OG001","value":"3.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.10","spread":null},{"groupId":"OG001","value":"0.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.50","spread":null},{"groupId":"OG001","value":"16.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.80","spread":null},{"groupId":"OG001","value":"14.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":null},{"groupId":"OG001","value":"0.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":null},{"groupId":"OG001","value":"16.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":null},{"groupId":"OG001","value":"2.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) Time as Determined by Investigator Assessment","description":"PFS was defined as the time from randomization until disease progression as determined by Investigator assessment or death from any cause, whichever occurred first during the pre-switch period. Disease progression was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 millimeters. Tumor assessments were performed prior to trial drug administration. PFS was calculated using the Kaplan-Meier technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.34","spread":null},{"groupId":"OG001","value":"9.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Time","description":"OS was defined as the time randomization until death from any cause during the pre-switch period. OS was calculated using the Kaplan-Meier technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.57","spread":null},{"groupId":"OG001","value":"19.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) as Determined by Investigator Assessment","description":"DOR was the time from first documented CR or PR until time of progression as determined by Investigator assessment during the pre-switch period. Tumor assessments were performed prior to trial drug administration. DOR was calculated using the Kaplan-Meier technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.66","spread":null},{"groupId":"OG001","value":"8.94","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":108,"n":335},"commonTop":["Alopecia","Anaemia","Nausea","Neuropathy peripheral","Neutropenia"]}}}